FY2025 EPS Estimate for Taysha Gene Therapies Cut by Analyst

Key Points

• Cantor Fitzgerald has downgraded its FY2025 earnings estimates for Taysha Gene Therapies, now predicting a loss of ($0.38) per share, compared to a prior estimate of ($0.33).
• The company reported a quarterly loss of ($0.09) per share, missing analysts' expectations, despite revenues of $1.99 million surpassing forecasts.
• Total institutional ownership in Taysha Gene Therapies is notably high at 77.70%, indicating strong investor interest in the stock.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Taysha Gene Therapies in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.38) per share for the year, down from their prior estimate of ($0.33). Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies' FY2026 earnings at ($0.52) EPS.

TSHA has been the topic of a number of other reports. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. Bank of America started coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They issued a "buy" rating and a $8.00 target price on the stock. Finally, Wells Fargo & Company boosted their target price on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a report on Wednesday, August 13th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has an average rating of "Buy" and an average price target of $8.29.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA traded down $0.01 during midday trading on Friday, reaching $2.93. The company's stock had a trading volume of 3,081,054 shares, compared to its average volume of 2,742,484. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average price of $2.61 and a 200 day moving average price of $2.13. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $3.31. The company has a market cap of $628.95 million, a price-to-earnings ratio of -8.62 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently made changes to their positions in TSHA. Ground Swell Capital LLC purchased a new position in Taysha Gene Therapies during the fourth quarter valued at approximately $25,000. E Fund Management Co. Ltd. purchased a new position in Taysha Gene Therapies during the second quarter valued at approximately $31,000. Hsbc Holdings PLC grew its position in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. May Hill Capital LLC purchased a new position in Taysha Gene Therapies during the second quarter valued at approximately $37,000. Finally, Ameriprise Financial Inc. purchased a new position in Taysha Gene Therapies during the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Insider Activity

In other news, major shareholder Paul B. Manning purchased 750,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were acquired at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the acquisition, the insider directly owned 2,841,704 shares of the company's stock, valued at $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.78% of the stock is owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.